CLEVELAND, July 26, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), makers of the world's only FDA-cleared MRI-guided radiation therapy system, announced today that the company's MRIdian® System is the focus of 55 abstracts selected by the American Association of Physicists in Medicine (AAPM) for presentation during their 2018 Annual Meeting. AAPM is the largest association of medical physicists in the world, and this year's meeting will be held July 29-August 2 in Nashville.

Presentations focused on MRIdian MRI-guided radiation therapy at this year's meeting include abstracts from global MRIdian institutions including Washington University, Henry Ford Health System, University of California Los Angeles (UCLA), University of Wisconsin, University of Miami, National Cancer Center Hospital in Tokyo, and Seoul National University Hospital.

Noteworthy abstracts featured in AAPM's Scientific Program include presentations from National Cancer Center Hospital in Tokyo and Washington University, both highlighting the benefits and quality of MRIdian's daily on-table adaptive and re-optimization capabilities in terms of both disease coverage and sparing of surrounding organs at risk. Presentations from Henry Ford Health System and National Cancer Center Hospital in Tokyo each showcase MRIdian's accurate treatment of tumors that move with respiration with excellent duty cycles (ratio of beam-on time to total treatment time).
Other presentations given by University of Miami and UCLA will highlight MRIdian's potential radiomics applications toward the assessment of disease origin and/or prediction of clinical response to treatment, including the potential ability to predict necrosis through longitudinal diffusion MRI.

AAPM attendees can also learn more about MRIdian and MRI-Guided Real-time, On-table, Adaptive Radiotherapy (ROAR) in ViewRay's booth #413 where MRIdian clinical users from UCLA, Washington University, University of Wisconsin, University of Miami, VUmc Amsterdam, and Henry Ford Health System will present throughout the meeting.

Also in the ViewRay booth will be demonstrations of the company's latest technological advances designed to improve tumor and soft tissue visualization as part of MRIdian's SmartVISIONTM technology. These technologies, which are currently pending 510(k) clearance1, include new T1w and T2w MR pulse sequences and Diffusion Weighted functional imaging (DWI) designed to enhance the contrast between cancerous and healthy tissues and potentially assess and predict tumor response to radiation therapy. Other potential enhancements from these technologies include a 2X increase in MR imaging speed as compared to previous generation systems, stepping up from 4 frames to 8 frames per second, along with 2X higher image resolution and a 2X improvement in MR signal-to-noise ratio (SNR) for brighter, more detailed anatomical imaging.

FDA 510(k) pending items are not available for sale or distribution in the United States.


About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that may potentially arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.


SOURCE ViewRay, Inc.

MRI Homepage